Eye drops for treating ocular vascular hyperplasia and preparation method thereof
Recombinant angiostatin and endostatin proteins were prepared using a Pichia pastoris expression system and used as eye drops to treat ocular angiogenesis. This solved the problem of unsatisfactory efficacy in existing technologies and achieved significant inhibitory effects and low-cost large-scale production.
CN122075401APending Publication Date: 2026-05-26海南省检验检测研究院
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202610207669.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-12
- Publication Date
- 2026-05-26
Smart Images
Figure CN122075401A_ABST
Abstract
The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.
Need to check novelty before this filing date? Find Prior Art